<DOC>
	<DOCNO>NCT01536028</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare pharmacodynamics pharmacokinetics single dose biphasic insulin aspart 30 , biphasic insulin aspart 50 , biphasic insulin aspart 70 insulin aspart subject type 1 diabetes .</brief_summary>
	<brief_title>Comparison Pharmacodynamics Pharmacokinetics Biphasic Insulin Aspart 30 , 50 , 70 Insulin Aspart Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 diabetes least 12 month Serum Cpeptide maximum 0.4 ng/mL Current basal bolus treatment soluble human insulin , insulin lispro , insulin glulisine , NPH insulin , insulin detemir insulin glargine BMI ( Body Mass Index ) maximum 32 kg/m^2 HbA1c ( glycosylated haemoglobin ) maximum 9 % base analysis central laboratory Nonsmoker The receipt investigational drug within last 30 day prior trial Total daily insulin dose least 1.8 U/kg/day Current treatment IAsp ( insulin aspart ) product A history drug alcohol abuse within last 5 year Impaired hepatic function Impaired renal function Cardiac problem Severe , uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>